New approach for treating cystic fibrosis shows success in mice
Researchers have developed a potential strategy to treat cystic fibrosis, using oligonucleotides to correct certain gene defects.
List view / Grid view
Researchers have developed a potential strategy to treat cystic fibrosis, using oligonucleotides to correct certain gene defects.
Researchers have found that the CDK inhibitor AT7519 could be used to treat pancreatic cancer patients whose tumours are addicted to mutant KRAS.
A new radiopharmaceutical compound has shown success at treating ovarian cancer in mice and in vitro studies.
Drug molecules from pine and spruce trees can affect certain ion channels and had antiseizure effects in pre-clinical studies.
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
Scientists have discovered that hepatic stellate cells are key in allowing dormant cancer cells to awaken and form fatal metastases.
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
Researchers have explored the interaction between SARS-CoV-2 RNA and the host cell, uncovering possible targets to prevent viral replication.
Using computer modelling, a team has shown that a molecular chaperone called GRP78 could be targeted by drugs in strategies to treat COVID-19.
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
A critical stage of the SARS-CoV-2 replication process, known as frameshifting, could be targeted by new drugs, researchers say.
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) can block cell death, new research has shown, making it a cancer drug target.
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.
Researchers have found that a metabolite of remdesivir potentially targets a SARS-CoV-2 protein involved in suppressing the host cell's defence response.